SIGNPATH PHARMA INC. Private Placement of Units PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • March 31st, 2014 • SignPath Pharma, Inc. • Pharmaceutical preparations • New York
SignPath Pharma Inc., a Delaware corporation (the “Company”) proposes to offer for sale (the “Offering”) in a private offering pursuant to Section 4(a)(2) and/or Section 4(a)(6) of the Securities Act of 1933, as amended (the “Act”), and Rule 506 of Regulation D promulgated thereunder, a $3,000,000 no minimum basis (the Maximum Offering”) of units (“Units”), with a $2,000,000 Over-Subscription Option. Each Unit offered at $1,000 consists of (i) one share of Series C Convertible Preferred Stock convertible into 800 shares of Common Stock issuable at $1.25 per share, and (ii) 400 Class C Warrants exercisable at $1.875 per share (the “Warrants”) to purchase an aggregate of 400 shares of Common Stock. The Units are being offered during an offering period commencing on the date hereof and expiring on June 30, 2013, unless mutually extended by the Company and Meyers Associates L.P. (the “Placement Agent”). This Agreement shall confirm our agreement concerning Meyers Associates L.P. acting as
EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2014 • SignPath Pharma, Inc. • Pharmaceutical preparations • Pennsylvania
AGREEMENT made the 20th day of February 2013 by and between Lawrence Helson, MD (hereinafter referred to as the “Employee”) and SignPath Pharma, Inc. (the “Company”), a Delaware Corporation.
